PRELUDE THERAPEUTICS INC
PRLDNASDAQTrading Snapshot
- Day Range
- $3.85 – $4.16
- 52-Week Range
- $1.17 – $6.83
- Volume (shares)
- 475,050
- Avg Volume (shares)
- —
- Shares Outstanding
- 57.9M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $12M
- Last Q Revenue
- $6M
- P/E Ratio
- -5.2
- P/S Ratio
- 10.7x
- EPS (TTM)
- $-0.61
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −17.1%
PRELUDE THERAPEUTICS INC
PRLD
StockOtter · stockotter.spaceAbout PRELUDE THERAPEUTICS INC
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
Prelude Therapeutics NASDAQ: PRLD outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer a
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Charda
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could le
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Combination cohorts are part of Prelude's Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026
Head to Head Review: Surrozen (NASDAQ:SRZN) and Prelude Therapeutics (NASDAQ:PRLD)
Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Surrozen (NASDAQ: SRZN - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on t
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock Rated “Moderate Buy” by Sell-Side Analysts
Shares of Prelude Therapeutics Incorporated (NASDAQ: PRLD - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six brokerages that are presently covering the stock, MarketBeat reports. One e